• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Jounce Therapeutics Receives FDA Clearance of Investigational NDA for Anti-CCR8 Antibody americanpharmaceuticalreview
    June 17, 2021
    Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the U.S. FDA's clearance of its Investigational New Drug (IND) application for JTX-1811 ...
  • Celgene licenses antibody JTX-8064 from Jounce for $50m pharmaceutical-technology
    July 25, 2019
    Global biopharma company Celgene has updated its 2016 strategic collaboration with clinical stage-focused Jounce Therapeutics and has decided to license global rights to JTX-8064; Celgene will now be responsible for all development and commercialisation o

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service